NRIX
Nurix Therapeutics Inc
NASDAQ: NRIX · HEALTHCARE · BIOTECHNOLOGY
$16.70
+0.54% today
Updated 2026-04-30
Market cap
$1.72B
P/E ratio
—
P/S ratio
23.93x
EPS (TTM)
$-3.17
Dividend yield
—
52W range
$8 – $23
Volume
1.1M
Nurix Therapeutics Inc (NRIX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-31.68M | $601000.00 | $-80000.00 | $-84.36M | $-159.81M | $-81.36M | $-172.58M | $-249.47M |
| Capital expenditures | $1.59M | $1.65M | $4.55M | $5.66M | $12.24M | $8.40M | $9.27M | $14.00M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $431000.00 | $510000.00 | $4.30M | $15.80M | $28.13M | $33.67M | $33.93M | $37.97M |
| Free cash flow | $-33.27M | $-1.05M | $-4.63M | $-90.03M | $-172.05M | $-89.77M | $-181.86M | $-263.47M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $84.54M | $-38.73M | $-15.42M | — | — | — |